Key result
Initiating digoxin in AF is linked to ~78% higher mortality versus matched controls.
Why the study?
Digoxin is widely used in AF, but whether its use is independently associated with increased mortality and if this is modified by heart failure or serum digoxin concentration remained unclear.
Does digoxin use increase mortality in patients with atrial fibrillation?
Cohort (n=17,897)
Does digoxin use increase mortality in patients with atrial fibrillation?
In patients with atrial fibrillation, initiating digoxin and having serum concentrations ≥1.2 ng/ml are independently associated with increased mortality, regardless of concomitant heart failure.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This was a really, truly, beautiful observational analysis. I think in cardiology, where our hearts have been broken before due to flawed observational studies, it's really important for people to understand that observational data, when analyzed well, with appropriate propensity matching, can still be very useful.”
“Lopes et al. have put their stake in the ground on the topic in this issue of the Journal.”
“The TREAT-AF study, however, was a controlled study that showed increased mortality in digoxin treated patients, but this was not a true randomized controlled clinical trial because it used propensity matching to create the control group.”
New digoxin initiation was associated with higher mortality in AF; hypothesis-generating and requires randomized confirmation before changing practice.
BACKGROUND: Digoxin is widely used in patients with atrial fibrillation (AF). OBJECTIVES: The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and if the association was modified by heart failure and/or serum digoxin concentration. METHODS: The association between digoxin use and mortality was assessed in 17,897 patients by using a propensity score-adjusted analysis and in new digoxin users during the trial versus propensity score-matched control participants. The authors investigated the independent association between serum digoxin concentration and mortality after multivariable adjustment. RESULTS: At baseline, 5,824 (32.5%) patients were receiving digoxin. Baseline digoxin use was not associated with an increased risk of death (adjusted hazard ratio [HR]: 1.09; 95% confidence interval [CI]: 0.96 to 1.23; p = 0.19). However, patients with a serum digoxin concentration ≥1.2 ng/ml had a 56% increased hazard of mortality (adjusted HR: 1.56; 95% CI: 1.20 to 2.04) compared with those not on digoxin. When analyzed as a continuous variable, serum digoxin concentration was associated with a 19% higher adjusted hazard of death for each 0.5-ng/ml increase (p = 0.0010); these results were similar for patients with and without heart failure. Compared with propensity score-matched control participants, the risk of death (adjusted HR: 1.78; 95% CI: 1.37 to 2.31) and sudden death (adjusted HR: 2.14; 95% CI: 1.11 to 4.12) was significantly higher in new digoxin users. CONCLUSIONS: In patients with AF taking digoxin, the risk of death was independently related to serum digoxin concentration and was highest in patients with concentrations ≥1.2 ng/ml. Initiating digoxin was independently associated with higher mortality in patients with AF, regardless of heart failure.
No takes yet. Share an insight, caveat, or question.
Lópes et al. (2018) conducted a cohort in atrial fibrillation (n=17,897). Digoxin vs. Patients not on digoxin / propensity score-matched controls was evaluated on death (HR 1.09, 95% CI 0.96 to 1.23, p=0.19). Initiating digoxin in patients with atrial fibrillation was associated with a higher risk of death compared to matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: